Immune checkpoint inhibitors to treat cutaneous malignancies Miscellaneous

   


Authors: Barrios, D. M.; Do, M. H.; Phillips, G. S.; Postow, M. A.; Akaike, T.; Nghiem, P.; Lacouture, M. E.
Title: Immune checkpoint inhibitors to treat cutaneous malignancies
Abstract: As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter immune checkpoint inhibitors. While the blockade of immune checkpoint target proteins (cytotoxic T-lymphocyte–associated protein-4, programmed cell death-1, and programmed cell death ligand-1) generates an antitumor response in a substantial fraction of patients, there is a critical need for reliable predictive biomarkers and approaches to address refractory disease. The first article of this Continuing Medical Education series reviews the indications, efficacy, safety profile, and evidence supporting checkpoint inhibition as therapeutics for metastatic melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. Pivotal studies resulting in the approval of ipilimumab, pembrolizumab, nivolumab, cemiplimab, and avelumab by regulatory agencies for various cutaneous malignancies, as well as ongoing clinical research trials, are discussed. © 2020 American Academy of Dermatology, Inc.
Keywords: melanoma; basal cell carcinoma; skin cancer; immunotherapy; merkel cell carcinoma; kaposi sarcoma; cutaneous squamous cell carcinoma; cutaneous lymphomas; checkpoint inhibitor; pd-1 inhibitor; pd-l1 inhibitor; ctla-4 inhibitor; cutaneous malignancies
Journal Title: Journal of the American Academy of Dermatology
Volume: 83
Issue: 5
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Date Published: 2020-11-01
Start Page: 1239
End Page: 1253
Language: English
DOI: 10.1016/j.jaad.2020.03.131
PUBMED: 32461079
PROVIDER: scopus
PMCID: PMC7572574
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092407967&doi=10.1016%2fj.jaad.2020.03.131&partnerID=40&md5=a9b5da44b9e66dae31c9a06eccaf433f
Notes: Review -- Export Date: 2 November 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Mario E Lacouture
    457 Lacouture
  2. Michael Andrew Postow
    362 Postow
  3. Mytrang Do
    16 Do
  4. Dulce M Barrios
    13 Barrios
Related MSK Work